US FDA's Abernethy 'Cautious' About Real-World Evidence

FDA's principal deputy commissioner, who used to work in the real-world evidence field, said momentum is building, but more successful use cases are needed.

FDA Principle Deputy Commissioner Amy Abernethy speaking to a Pharmaceutical Research and Manufacturers of America conference
US FDA Principal Deputy Commissioner Amy Abernethy said companies must "pressure test" RWE ideas to prove their viability. • Source: Derrick Gingery

The US Food and Drug Administration's No. 2, who came to the agency from a company pushing for increased use of real-world evidence, is not convinced the data is ready for full implementation in drug development.

Amy Abernethy, the agency's principal deputy commissioner, told an industry audience that momentum is building for increased use of RWE,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Real-World Evidence

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

EMA Advances Use Of Real-World Data By HTAs And Payers

 
• By 

Results from the first pilot real-world evidence study commissioned by the European Medicines Agency to help HTA bodies and payers characterize patients with multiple myeloma have drawn positive feedback.

EU Ocaliva Withdrawal Recommendation Based On ‘Flawed’ Studies

 

Overreliance on “problematic” trials while overlooking the value of real-world evidence could affect the development of other rare disease treatments, according to Advanz’s CEO.

More from Clinical Trials

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.